Sydney, May 11, 2026, 08:02 AEST
Cochlear Limited is set to reopen Monday near A$100 a share, a level that now frames investor confidence after last month’s sharp profit cut and share-price collapse. MarketScreener data showed the stock closed May 8 at A$99.89, up 1.7% on the day but still down 61.7% for the year.
At 08:02 AEST, the ASX cash market was in pre-open, when brokers can queue orders but trades do not yet match. Normal trading starts at about 09:59:45 Sydney time, putting Cochlear’s first print under quick scrutiny.
The timing is not clean. Reuters reported the S&P/ASX 200 closed down 1.5% on Friday at 8,744.40 as renewed Middle East tension curbed risk appetite, leaving investors less forgiving toward companies with exposed earnings forecasts.
Cochlear cut FY26 underlying net profit — a company profit measure that strips out some one-off or non-recurring items — to A$290 million-A$330 million. It said second-half sales growth would be 2%-6% in constant currency, meaning before exchange-rate moves, after softer developed-market implant demand, hospital capacity limits, weaker referrals from hearing-aid channels, Middle East delivery and order risks, and a stronger Australian dollar. Chief Executive Dig Howitt said the company needed to “medicalise hearing loss” so adult and senior treatment is viewed as a health priority. Cochlear Assets
The cut came only two months after February guidance had pointed to the low end of A$435 million-A$460 million. Cochlear shares lost 40.7% on April 22 to close at A$99.58, a record daily fall and their weakest close since March 2016; Reuters said the new midpoint missed Visible Alpha’s A$402.5 million consensus by a wide margin.
Analysts were blunt. Jarden analyst Steve Wheen called the downgrade “far worse than anticipated” and raised concerns over forecast reliability. E&P analyst Sacha Krien said the cut reflected weaker developed-market implant volumes, emerging-market uncertainty, margin pressure and restructuring costs, while Wilson Asset Management portfolio manager Anna Milne said valuation improvement would need signs of demand recovery. Wilson Asset Management
But the risk is that this was not just a temporary surgery-delay problem. Morningstar analyst Shane Ponraj cut Cochlear’s fair value estimate by 51% to A$110 and said the headwinds looked more structural; his note lowered average 10-year revenue and underlying profit forecasts by 14% and 35%, respectively, citing U.S. cost pressures and European hospital capacity limits.
The read-through went beyond one ASX stock. Sonova, Demant and Amplifon slipped after Cochlear’s warning, according to Finwire, which said those hearing-health companies also have significant North American exposure.
Cochlear still has scale. Its HY26 presentation said the Sydney-based company sells in more than 180 countries, employs more than 5,500 people and has helped more than 750,000 people hear with implantable solutions; it also estimates fewer than 5% of people who could benefit from an implantable hearing solution have received one.
For Monday, the immediate test is narrower: whether Cochlear can hold around Friday’s A$100 level while investors wait for proof that adult and senior implant demand, not only cost reshaping, has steadied.
